Skip to main content
. Author manuscript; available in PMC: 2018 Sep 1.
Published in final edited form as: J Clin Lipidol. 2017 Jul 5;11(5):1201–1211. doi: 10.1016/j.jacl.2017.06.017

Figure 3. Time to Primary Endpoint by Risk Gradient.

Figure 3

Kaplan-Meier estimates of time to primary endpoint in participants stratified by risk gradient

DM = history of diabetes mellitus at baseline, negative (−) or positive (+)

MS=metabolic syndrome at baseline, negative (−) or positive (+)